Lifesaving drug made available for rare fat disorder patients
NCT ID NCT02262832
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study gives the drug metreleptin to people with generalized lipodystrophy, a rare condition that causes severe fat loss and leads to high blood fats and diabetes. Participants, aged 6 months and older, have already received metreleptin in past NIH studies but cannot get it in their home country. The goal is to keep their blood fats and blood sugar under control with ongoing treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Text messages and nurses: a new strategy to tackle hypertension in tanzania?
- Could diabetes be silently damaging your hearing?
- Press play on better health: could recording doctor visits boost Self-Care in seniors?
- Could a simple breakfast replace the glucose drink for diabetes testing?
- Putting Patients' priorities first: a new approach to ease the burden of multiple chronic illnesses
- A simple card game could transform diabetes care